Goals of managing patients with acute kidney injury (AKI) are mitigating disease progression and ensuring safety while providing supportive care because no effective treatment exists. One strategy recommended in guidelines to meet these goals is optimizing medication management. Unfortunately, guideline implementation appears to be lacking as observed by the frequent occurrence of medication errors and adverse drug events.
Objective:
To address this performance gap in the care of hospitalized patients receiving nephrotoxins and renally eliminated drugs, we sought to provide a potential intervention based on theory-informed behavior change.
Methods:
Formative research with a qualitative analysis identifying what needs to change in patient care was completed by obtaining clinician opinion and expert opinion and reviewing the published literature. Frontline providers, including 8 physicians, 4 pharmacists, and a multiprofessional group of authors, provided insight into possible barriers to appropriate prescribing. Capability, Opportunity, Motivation and Behavior model and Theoretical Domain Framework were applied to characterize behavior change interventions and inform a potential implementation intervention for changing inappropriate prescribing behaviors.
Results:
Lack of knowledge about appropriate drug management in patients at risk for adverse outcomes was provided as a major barrier. Other reported barriers included a lack of: (1) tools to assist with drug management, (2) motivation to make changes, (3) routinization, and (4) an accountable clinician.
Conclusions and Relevance:
Assigning a designated clinician to execute a stepwise, routine care process following the checklist provided is a recommended intervention to overcome barriers. The intended impact is behavior change that reduces inappropriate prescribing.
SusantitaphongPCruzDNCerdaJ, et al; Acute Kidney Injury Advisory Group of the American Society of Nephrology. World incidence of AKI: a meta-analysis. Clin J Am Soc Nephrol. 2013;8:1482-1493. doi:10.2215/CJN.00710113
2.
HosteEABagshawSMBellomoR, et al. Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. Intensive Care Med. 2015;41:1411-1423. doi:10.1007/s00134-015-3934-7
3.
ChawlaLSBellomoRBihoracA, et al. Acute kidney disease and renal recovery: consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup. Nat Rev Nephrol. 2017;13:241-257. doi:10.1038/nrneph.2017.2
4.
GoldsteinSLDahaleDKirkendallES, et al. A prospective multi-center quality improvement initiative (NINJA) indicates a reduction in nephrotoxic acute kidney injury in hospitalized children. Kidney Int. 2020;97:580-588. doi:10.1016/j.kint.2019.10.015
5.
JelliffeR.Estimation of creatinine clearance in patients with unstable renal function, without a urine specimen. Am J Nephrol. 2002;22:320-324. doi:10.1159/000065221
6.
CoxZLMcCoyABMathenyME, et al. Adverse drug events during AKI and its recovery. Clin J Am Soc Nephrol. 2013;8:1070-1078. doi:10.2215/CJN.11921112
7.
LongCLRaebelMAPriceDWMagidDJ.Compliance with dosing guidelines in patients with chronic kidney disease. Ann Pharmacother. 2004;38:853-858. doi:10.1345/aph.1D399
8.
CrassRLRodvoldKAMuellerBAPaiMP.Renal dosing of antibiotics: are we jumping the gun?Clin Infect Dis. 2019;68:1596-1602. doi:10.1093/cid/ciy790
MatzkeGRAronoffGRAtkinsonAJJr, et al. Drug dosing consideration in patients with acute and chronic kidney disease-a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2011;80:1122-1137. doi:10.1038/ki.2011.322
11.
OstermannMChawlaLSForniLG, et al. Drug management in acute kidney disease—report of the Acute Disease Quality Initiative XVI meeting. Br J Clin Pharmacol. 2018;84:396-403. doi:10.1111/bcp.13449
12.
CowdellFDysonJ.How is the theoretical domains framework applied to developing health behaviour interventions? A systematic search and narrative synthesis. BMC Public Health. 2019;19:1180. doi:10.1186/s12889-019-7442-5
13.
TaylorNLawtonRSlaterBFoyR.The demonstration of a theory-based approach to the design of localized patient safety interventions. Implement Sci. 2013;8:123. doi:10.1186/1748-5908-8-123
14.
SmithMABlanchardCMVuernickE.The intersection of implementation science and pharmacy practice transformation. Ann Pharmacother. 2020;54:75-81. doi:10.1177/1060028019867253
15.
MichieSvan StralenMMWestR.The behaviour change wheel: a new method for characterising and designing behaviour change interventions. Implement Sci. 2011;6:42. doi:10.1186/1748-5908-6-42
16.
MichieSAtkinsLWestR.The Behaviour Change Wheel: A Guide to Designing Interventions. Silverback Publishing; 2014.
17.
RobertLFicheurGGautierS, et al. Community-acquired acute kidney injury induced by drugs in older patients: a multifactorial event. Clin Interv Aging. 2019;14:2105-2113. doi:10.2147/CIA.S217567
18.
Drenth-van MaanenACvan MarumRJJansenPAZwartJEvan SolingeWWEgbertsTC.Adherence with dosing guideline in patients with impaired renal function at hospital discharge. PLoS One. 2015;10:e0128237. doi:10.1371/journal.pone.0128237
19.
RivosecchiRMKellumJADastaJF, et al. Drug class combination-associated acute kidney injury. Ann Pharmacother. 2016;50:953-972. doi:10.1177/1060028016657839
20.
TawadrousDShariffSZHaynesRBIansavichusAVJainAKGargAX.Use of clinical decision support systems for kidney-related drug prescribing: a systematic review. Am J Kidney Dis. 2011;58:903-914. doi:10.1053/j.ajkd.2011.07.022
21.
TullyMPAshcroftDMDornanTLewisPJTaylorDWassV.The causes of and factors associated with prescribing errors in hospital inpatients: a systematic review. Drug Saf. 2009;32:819-836. doi:10.2165/11316560-000000000-00000
22.
LeapeLEpsteinAMHamelMB.A series on patient safety. N Engl J Med. 2002;347:1272-1274. doi:10.1056/NEJMe020123
23.
SlightSPHowardRGhalebMBarberNFranklinBDAveryAJ.The causes of prescribing errors in English general practices: a qualitative study. Br J Gen Pract. 2013;63:e713-e720. doi:10.3399/bjgp13X673739
24.
GoswamiEOgdenRKBennettWE, et al. Evidence-based development of a nephrotoxic medication list to screen for acute kidney injury risk in hospitalized children. Am J Health Syst Pharm. 2019;76:1869-1874. doi:10.1093/ajhp/zxz203
25.
TajiLBattistellaMGrillAK, et al. Medications used routinely in primary care to be dose-adjusted or avoided in people with chronic kidney disease: results of a modified Delphi study. Ann Pharmacother. 2020;54:625-632. doi:10.1177/1060028019897371
26.
HugBLWitkowskiDJSoxCM, et al. Occurrence of adverse, often preventable, events in community hospitals involving nephrotoxic drugs or those excreted by the kidney. Kidney Int. 2009;76:1192-1198. doi:10.1038/ki.2009.353
27.
HassanYAl-RamahiRJAzizNAGhazaliR.Impact of a renal drug dosing service on dose adjustment in hospitalized patients with chronic kidney disease. Ann Pharmacother. 2009;43:1598-1605. doi:10.1345/aph.1M187
28.
BelaicheSRomanetTAllenetBCalopJZaouiP.Identification of drug-related problems in ambulatory chronic kidney disease patients: a 6-month prospective study. J Nephrol. 2012;25:782-788. doi:10.5301/jn.5000063
29.
LeBlancJMKane-GillSLPohlmanASHerrDL.Multiprofessional survey of protocol use in the intensive care unit. J Crit Care. 2012;27:738.e9-e17. doi:10.1016/j.jcrc.2012.07.012
30.
van DiepenSSliglWIWashamJBGilchristICAroraRCKatzJN.Prevention of critical care complications in the coronary intensive care unit: protocols, bundles, and insights from intensive care studies. Can J Cardiol. 2017;33:101-109. doi:10.1016/j.cjca.2016.06.011
31.
Al-JaghbeerMDealmeidaDBilderbackAAmbrosinoRKellumJA.Clinical decision support for in-hospital AKI. J Am Soc Nephrol. 2018;29:654-660. doi:10.1681/ASN.2017070765
32.
CasselCKGuestJA.Choosing wisely: helping physicians and patients make smart decisions about their care. JAMA. 2012;307:1801-1802. doi:10.1001/jama.2012.476
33.
ChertowGMLeeJKupermanGJ, et al. Guided medication dosing for inpatients with renal insufficiency. JAMA. 2001;286:2839-2844. doi:10.1001/jama.286.22.2839
34.
GalanterWLDidomenicoRJPolikaitisA.A trial of automated decision support alerts for contraindicated medications using computerized physician order entry. J Am Med Inform Assoc. 2005;12:269-274. doi:10.1197/jamia.M1727
35.
GoldsteinSLMottesTSimpsonK, et al. A sustained quality improvement program reduces nephrotoxic medication-associated acute kidney injury. Kidney Int. 2016;90:212-221. doi:10.1016/j.kint.2016.03.031
36.
KoynerJLAdhikariREdelsonDPChurpekMM.Development of a multicenter ward-based AKI prediction model. Clin J Am Soc Nephrol. 2016;11:1935-1943. doi:10.2215/CJN.00280116
37.
MurphyEV.Clinical decision support: effectiveness in improving quality processes and clinical outcomes and factors that may influence success. Yale J Biol Med. 2014;87:187-197.
38.
MeerschMSchmidtCHoffmeierA, et al. Prevention of cardiac surgery-associated AKI by implementing the KDIGO guidelines in high risk patients identified by biomarkers: the PrevAKI randomized controlled trial. Intensive Care Med. 2017;43:1551-1561. doi:10.1007/s00134-016-4670-3
39.
GoczeIJauchDGotzM, et al. Biomarker-guided intervention to prevent acute kidney injury after major surgery: the prospective randomized BigpAK study. Ann Surg. 2018;267:1013-1020. doi:10.1097/SLA.0000000000002485
40.
Kane-GillSLBauerSR.AKD—the time between AKI and CKD: what is the role of the pharmacist?Hosp Pharm. 2017;52:663-665. doi:10.1177/0018578717733561
41.
Davis-AjamiMLFinkJCWuJ.Nephrotoxic medication exposure in U.S. adults with predialysis chronic kidney disease: health services utilization and cost outcomes. J Manag Care Spec Pharm. 2016;22:959-968. doi:10.18553/jmcp.2016.22.8.959
42.
FrolichTZorinaOFontanaAOKullak-UblickGAVollenweiderARussmannS.Evaluation of medication safety in the discharge medication of 509 surgical inpatients using electronic prescription support software and an extended operational interaction classification. Eur J Clin Pharmacol. 2011;67:1273-1282. doi:10.1007/s00228-011-1081-9
43.
SahSKWanakamaneeULerkiatbunditSRegmiBM.Drug dosage adjustment of patients with impaired renal function at hospital discharge in a teaching hospital. J Nepal Health Res Counc. 2014;12:54-58.
44.
van DijkEADrabbeNRKruijtboschMDe SmetPA.Dosage adjustments according to renal function at discharge: a comparison of 3 hospitals. Ann Pharmacother. 2006;40:2276-2277. doi:10.1345/aph.1H380
45.
MekonnenABMcLachlanAJBrienJAE. Pharmacy-led medication reconciliation programmes at hospital transitions: a systematic review and meta-analysis. J Clin Pharm Ther. 2016;41:128-144. doi:10.1111/jcpt.12364
46.
BonettiAFReisWCMendesAM, et al. Impact of pharmacist-led discharge counseling on hospital readmission and emergency department visits: a systematic review and meta-analysis. J Hosp Med. 2020;15:52-59. doi:10.12788/jhm.3182
47.
MarbachJAJohnsonDKlooJ, et al. The impact of a transition of care program on acute myocardial infarction readmission rates. Am J Med Qual. 2018;33:481-486. doi:10.1177/1062860618754702
48.
Kane-GillSLDastaJFBuckleyMS, et al. Clinical practice guideline: safe medication use in the ICU. Crit Care Med. 2017;45:e877-e915. doi:10.1097/CCM.0000000000002533
49.
ClassenDCPestotnikSLEvansRSLloydJFBurkeJP.Adverse drug events in hospitalized patients: excess length of stay, extra costs, and attributable mortality. JAMA. 1997;277:301-306.
50.
BatesDWSpellNCullenDJ, et al. The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group. JAMA. 1997;277:307-311.
51.
GaglioBShoupJAGlasgowRE.The RE-AIM framework: a systematic review of use over time. Am J Public Health. 2013;103:e38-e46. doi:10.2105/AJPH.2013.301299
52.
CrosbyRNoarSM.What is a planning model? An introduction to PRECEDE-PROCEED. J Public Health Dent. 2011;71(suppl 1):S7-S15. doi:10.1111/j.1752-7325.2011.00235.x
53.
AndersonKStowasserDFreemanCScottI.Prescriber barriers and enablers to minimising potentially inappropriate medications in adults: a systematic review and thematic synthesis. BMJ Open. 2014;4:e006544. doi:10.1136/bmjopen-2014-006544
54.
DwivediYKRanaNPTamilmaniKRamanR.A meta-analysis based modified unified theory of acceptance and use of technology (meta-UTAUT): a review of emerging literature. Curr Opin Psychol. 2020;36:13-18. doi:10.1016/j.copsyc.2020.03.008
55.
YusofMMKuljisJPapazafeiropoulouAStergioulasLK.An evaluation framework for Health Information Systems: human, organization and technology-fit factors (HOT-fit). Int J Med Inform. 2008;77:386-398. doi:10.1016/j.ijmedinf.2007.08.011
56.
CamachoJZanoletti-MannelloMLandis-LewisZKane-GillSLBoyceRD.A Conceptual framework to study the implementation of clinical decision support systems (BEAR): literature review and concept mapping. J Med Internet Res. 2020;22:e18388. doi:10.2196/18388
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
